Salarius Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 15, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Flex Pharma, Inc. (FLKS)
CIK: 0001615219
Period of Report: 2016-03-11

Reporting Person: Wessel Thomas (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-11	Common Stock	P	12000	$7.15	Acquired	49064	Direct
2016-03-14	Common Stock	P	8000	$9.13	Acquired	57064	Direct

Footnotes

F1: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $6.91 to $7.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.

F2: The price in Column 4 is a weighted average purchase price. The prices actually received ranged from $7.69 to $9.58. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.